Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Concizumab prophylaxis in severe haemophilia A without inhibitors (explorer5)
NCT03196297Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Aug 2017
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 11
01
Overview
Phase 2, open-label, single-arm trial of concizumab in hemophilia A, sponsored by Novo Nordisk. Primary endpoint: The Number of Bleeding Episodes During at Least 24 Weeks From Treatment Onset. Started Aug 2017; status: completed.
02
Drugs
concizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT03196297.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03196297.